Our Leadership

About Us

Joseph A. Helpern, PhD

Chairman, Board of Directors and Chief Science Advisor

Joseph Helpern is an internationally recognized physicist for his contributions to the field of imaging in neurodegenerative disorders. At New York University’s Grossman School of Medicine, Dr. Helpern held appointments as Vice Chair of Radiology, Director of the Center for Biomedical Imaging and Professor of Psychiatry, Physiology and Neuroscience. More recently, Dr. Helpern was a Professor of Radiology, Neuroscience and Neurology at the Medical University of South Carolina where he also held the Levidow Family Distinguished Chair in Neurodegenerative Disease Research.

Among Dr. Helpern’s awards are the Excellence in Research Award from the New York State Office of Mental Health, the Distinguished Investigator Award from the Academy of Radiology Research and the Distinguished Alumni Award from Oakland University. Dr. Helpern has served on numerous NIH panels including President Obama’s BRAIN initiative. He received his BA in Chemistry from Case Western Reserve University, his MA in Chemistry from the University of North Carolina at Chapel Hill and his Ph.D. in Medical Physics from Oakland University.
About Us

Jennifer Sessions

Chief Executive Officer

Jennifer Sessions has more than 20 years of research and development experience in both industry and academia, including work at Eli Lilly & Co., The University of North Carolina, and the Medical University of South Carolina. Mrs. Sessions has specific expertise in the areas of clinical development, clinical operations, clinical trial management, Six Sigma, and pharmaceutical project management. She also has experience in clinical project management for oncology programs in early stage development.

Mrs. Sessions received her BA in Psychology and Criminal Justice from Indiana University and her MS in Counseling Psychology from Indiana State University where she graduated Summa Cum Laude. She is a certified Six Sigma Black Belt.
About Us

Mark Gelnaw

Chief Financial Officer

Mark Gelnaw has significant experience in the financial services industry, having held senior positions at Lehman Brothers, Salomon Brothers and Arthur Andersen as well as Global Head of Business Development and Head of Strategic Funds for the Asset Management division of Deutsche Bank. He also served as COO for Deutsche Bank’s Equity and Asset Management divisions, Global Head of Equity Finance and Global Head of Proprietary Trading and Portfolio Manager of the Deutsche Bank Angel Fund.

Mr. Gelnaw currently participates in various development stage private equity ventures and is President and CEO of Breakwater Ventures. He is a graduate of Georgetown University where he received his BSBA in Accounting. Mr. Gelnaw is a Certified Public Accountant and holds Series 7 – General Securities Representative, and Series 63 – Uniform Securities State Law, licenses.
About Us

Daniel Meruelo, PhD

Inventor, Lead Scientist

Daniel Meruelo is a Professor in the Department of Pathology and Director of New York University Grossman School of Medicine’s Gene Therapy Center. Dr. Meruelo received his Ph.D. in biochemistry/Immunology from John Hopkins University in 1974 and was a Postdoctoral Fellow in Immunogenetics at Stanford University.

Dr. Meruelo has received funding from Cynvec and the National Institutes of Health (NIH), the Department of Defense and other foundations for his research efforts on oncolytic Sindbis viral vectors. He has published over 100 peer-reviewed articles in leading medical and research journals.